Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer

Joshua Tobias*, Mirjana Drinić, Anna Schmid, Anastasiya Hladik, Martin L. Watzenböck, Claire Battin, Erika Garner-Spitzer, Peter Steinberger, Michael Kundi, Sylvia Knapp, Christoph C. Zielinski, Ursula Wiedermann*

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Review article

1 Citation (Scopus)


The application of monoclonal antibodies (mAbs), targeting tumor-associated (TAAs) or tumor-specific antigens or immune checkpoints (ICs), has shown tremendous success in cancer therapy. However, the application of mAbs suffers from a series of limitations, including the necessity of frequent administration, the limited duration of clinical response and the emergence of frequently pronounced immune-related adverse events. However, the introduction of mAbs has also resulted in a multitude of novel developments for the treatment of cancers, including vaccinations against various tumor cell-associated epitopes. Here, we reviewed recent clinical trials involving combination therapies with mAbs targeting the PD-1/PD-L1 axis and Her-2/neu, which was chosen as a paradigm for a clinically highly relevant TAA. Our recent findings from murine immunizations against the PD-1 pathway and Her-2/neu with peptides representing the mimotopes/B cell peptides of therapeutic antibodies targeting these molecules are an important focus of the present review. Moreover, concerns regarding the safety of vaccination approaches targeting PD-1, in the context of the continuing immune response, as a result of induced immunological memory, are also addressed. Hence, we describe a new frontier of cancer treatment by active immunization using combined mimotopes/B cell peptides aimed at various targets relevant to cancer biology.

Original languageEnglish
Article number5678
Issue number22
Publication statusPublished - Nov 2022
Externally publishedYes


  • active immunization
  • anti-tumor effect
  • combination therapy
  • Her-2/neu
  • immune checkpoints
  • mimotopes/B cell peptides
  • safety
  • vaccination

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer'. Together they form a unique fingerprint.

Cite this